FDA Calls For Class-Wide REMS For LABA Asthma Drugs
Executive Summary
On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures
You may also be interested in...
Six Years And Four Trials Later, LABA/ICS Combos Twist Free Of Box Warning
US FDA concludes that combination products do not increase risk of serious asthma-related events compared to inhaled corticosteroids alone.
Asthma Warnings Not Working Well, FDA Fears As GSK Seeks Expanded LABA Approval
LABA prescribing patterns haven’t changed despite FDA’s labeling instructions on asthma safety concerns, agency concludes.
GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim
LABA safety issues may come to haunt GlaxoSmithKline as FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will focus on the combination’s product’s safety database and whether an outcomes study is needed for approval in asthma.